Pharmaceutical Sciences at Federal University of Paraná.
Biochemistry at Federal University of Paraná.
Int J Technol Assess Health Care. 2018 Jan;34(2):180-188. doi: 10.1017/S026646231800017X. Epub 2018 Apr 10.
The aim of this study was to evaluate the direct costs of type 2 diabetes mellitus patients treated in a Brazilian public hospital.
This was an exploratory retrospective cost-of-illness study with quantitative approach, using medical records of patients treated in a public hospital (2012-14), with at least one consultation over a period of 12 months. Data on patient's profile, exams, number of consultations, medications, hospitalizations, and comorbidities were collected. The cost per patient per year (pppy) was calculated as well as the costs related to glycated hemoglobin (HbA1c) values, using thresholds of 7 and 8 percent.
Data of 726 patients were collected with mean age of 62 ± 11 years (68.3 percent female). A total of 67.1 percent presented HbA1c > 7 percent and 44.9 percent > 8 percent. The median cost of diabetes was United States dollar (USD) 197 pppy. The median costs of medication were USD 152.49 pppy, while costs of exams and consultations were USD 40.57 pppy and 8.70 pppy, respectively. Thirty-eight patients (4 percent) were hospitalized and presented a median cost of 3,656 per patient per hospitalization with a cost equivalent to 53.1 percent of total expenses. Total costs of patients with HbA1c ≤ 7 percent were lower for this group and also costs of medications and consultations, whereas for patients with HbA1c ≤ 8 percent, only total costs and costs of medications were lower when compared with HbA1c > 8 percent patients.
Medications and hospitalizations were the major contributor of diabetes expenses. Preventing T2DM, or reducing its complications through adequate control, may help avoid the substantial costs related to this disease.
本研究旨在评估在巴西一家公立医院接受治疗的 2 型糖尿病患者的直接医疗费用。
这是一项探索性回顾性疾病成本研究，采用定量方法，使用在公立医院（2012-14 年）接受治疗的患者病历，患者至少有一次为期 12 个月的就诊。收集患者特征、检查、就诊次数、药物、住院和合并症的数据。计算每位患者每年的费用（pppy），并根据糖化血红蛋白（HbA1c）值使用 7%和 8%的阈值计算相关费用。
共收集了 726 名患者的数据，平均年龄为 62±11 岁（68.3%为女性）。HbA1c 超过 7%的患者占 67.1%，超过 8%的患者占 44.9%。糖尿病的中位数费用为 197 美元（USD）pppy。药物的中位数费用为 152.49 美元（USD）pppy，而检查和就诊的中位数费用分别为 40.57 美元（USD）pppy 和 8.70 美元（USD）pppy。38 名患者（4%）住院，每位患者每次住院的中位数费用为 3656 美元，占总费用的 53.1%。HbA1c≤7%的患者总费用和药物及就诊费用均较低，而 HbA1c≤8%的患者总费用和药物费用均低于 HbA1c>8%的患者。
药物和住院是糖尿病费用的主要来源。预防 T2DM 或通过适当控制降低其并发症可能有助于避免与该疾病相关的巨额费用。
